Literature DB >> 6975241

Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients.

K Naber, H Vergin, W Weigand.   

Abstract

Following a single dose of co-trimoxazole or co-tetroxazine, the plasma and urine levels of intact trimethoprim (TMP) and sulphamethoxazole (SMZ) and of tetroxoprim and sulphadiazine (SDZ) were determined in six geriatric patients in a cross-over design by high pressure liquid chromatography. The pharmacokinetic analysis showed a plasma elimination half-life in the terminal phase of 10.39 h for TMP, 11.79 h for SMZ, 6.55 h for TXP and 10.46 h for SDZ. The resulting distribution volumes Vd beta and total plasma clearance values corresponded with the data obtained in young patients or volunteers. Recovery in urine, measured for up to 96 h, was 49.2% (TMP), 19.8% (SMZ), 57.03% (TXP) and 61.1% (SDZ). In contrast to young volunteers, geriatric patients experienced a slight prolongation of renal excretion for both sulphonamides. In this group of patients the renal clearance was 2.42 ml/min for SMZ and 10.7 ml/min for SDZ.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975241     DOI: 10.1007/BF01640724

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  A comparative clinical trial of tetroxoprim/sulphadiazine and ampicillin in the treatment of purulent bronchial infections.

Authors:  A Pines; H Raafat
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

2.  Open and comparative treatment studies with tetroxoprim/sulphadiazine combinations in urinary infections (1975--1979).

Authors:  D S Reeves; A J Bint; R Bowman; D W Bullock; P J Elliott; C E Hinton; D Honeybourne; Z Mojaddedi; R R Slade; P J Wilkinson
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

3.  Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function.

Authors:  J Rieder; D E Schwartz; M Fernex; T Bergan; E K Brodwall; A Blumberg; P Cottier; W Scheitlin
Journal:  Antibiot Chemother (1971)       Date:  1974

4.  Pharmacokinetics of sulfamethoxazole plus trimethoprim in man and their distribution in the rat.

Authors:  D E Schwartz; J Rieder
Journal:  Chemotherapy       Date:  1970       Impact factor: 2.544

5.  General survey of trimethoprim combinations in the treatment of urinary tract infections.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  Pharmacokinetics of tetroxoprim/sulphadiazine in patients with impaired renal function.

Authors:  F W Reutter; H Vergin; R Sieber; H Ferber
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

7.  Pharmacokinetics of tetroxoprim and sulphadiazine in various species.

Authors:  H Vergin; E Fritschi
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

8.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man.

Authors:  U Klotz; G R Avant; A Hoyumpa; S Schenker; G R Wilkinson
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

9.  [Pharmacokinetics of cefotaxim in geriatric patients (author's transl)].

Authors:  K Naber; D Adam
Journal:  MMW Munch Med Wochenschr       Date:  1980-11-14

10.  [High-performance liquid chromatographic determination of tetroxoprim and sulfadiazine in biological samples (author's transl)].

Authors:  H Vergin; G B Bishop
Journal:  Arzneimittelforschung       Date:  1980
View more
  2 in total

Review 1.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 2.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.